What is the recommended time frame for Non-Invasive Prenatal Testing (NIPT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 29, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

NIPT Testing Time Frame

NIPT should be performed at 10 weeks gestation or later, when approximately 10-15% of total cell-free DNA in maternal plasma is of placental origin, providing sufficient fetal fraction for accurate analysis. 1

Optimal Testing Window

  • The standard time frame for NIPT is after 10 weeks gestation, as recommended by the American College of Radiology and the American College of Obstetricians and Gynecologists. 1

  • First trimester use (10-14 weeks) is the evidence-based application of NIPT, with detection rates for trisomy 21 of 99% and false positive rates of 0.5% in women who receive results. 1

  • NIPT can be performed as early as 9 weeks gestation, though fetal fraction may be lower at very early gestational ages, making the test less likely to provide a result. 1, 2

Why This Timing Matters

  • Before 9-10 weeks, insufficient fetal fraction is the primary limitation, as adequate placental-derived cell-free DNA must be present in maternal circulation for reliable analysis. 1, 2

  • If a "no-call" result occurs at 9 weeks, repeat testing at a slightly later gestational age provides a result in approximately 75-80% of cases. 1, 2

  • The minimum fetal fraction required is approximately 4%, and testing at 10 weeks or later optimizes the likelihood of achieving adequate fetal fraction. 2

Clinical Algorithm for Timing

  • For pregnancies presenting in first trimester (before 14 weeks): Offer NIPT at 10 weeks or later for optimal fetal fraction. 1

  • For pregnancies presenting in second or third trimester: NIPT is not the appropriate screening modality; standard anatomic ultrasound screening at 18-22 weeks is recommended for structural anomalies, and if aneuploidy screening is desired, proceed directly to diagnostic testing (amniocentesis) rather than screening. 1

Important Caveats

  • The primary value of NIPT is early reassurance or early diagnosis, allowing time for diagnostic confirmation and reproductive decision-making. 1

  • NIPT remains a screening test, not diagnostic, and all positive results require confirmation with chorionic villus sampling (CVS) or amniocentesis regardless of when performed. 1, 2

  • NIPT cannot replace ultrasound for detection of structural anomalies and does not screen for neural tube defects, making it complementary to, not a replacement for, anatomic ultrasound evaluation. 1

  • Maternal factors affecting test performance include obesity, which is associated with low fetal fraction and up to 20% test failure in high BMI women, making alternative screening methods potentially more appropriate for this population. 1, 2

References

Guideline

Non-Invasive Prenatal Testing for Fetal Sex Determination

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Factors Associated with Low Fetal Fraction in Non-Invasive Prenatal Testing

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What are the NICE (National Institute for Health and Care Excellence) guidelines for offering Non-Invasive Prenatal Testing (NIPT)?
Can Non-Invasive Prenatal Testing (NIPT) be performed in all trimesters?
What is the recommended timing and procedure for Non-Invasive Prenatal Screening (NIPS) tests?
What is the recommended prenatal screening test for pregnant women of advanced maternal age or with a family history of genetic disorders, such as Non-Invasive Prenatal Testing (NIPT)?
Do I need Combined First Trimester Screening (CFTS) if I've had Non-Invasive Prenatal Testing (NIPT)?
What is the best course of treatment for a patient with type 2 diabetes (T2D), hypertension (HTN), bradycardia, impaired renal function, and an enlarged prostate, who is experiencing fatigue and excessive sleepiness, with lab results showing hyperglycemia (A1C 8.9), elevated creatinine (1.60), and elevated B-type natriuretic peptide (BNP) levels, and is currently taking Lantus (insulin glargine) 60 units, Janumet (sitagliptin and metformin), Losartan (losartan potassium) 100mg, Rosuvastatin (rosuvastatin calcium), Tamsulosin (tamsulosin hydrochloride), and Metoprolol (metoprolol tartrate) 12.5mg?
What is the next step in managing a patient with emphysema presenting with rhonchi?
What are suitable high blood pressure medications for a patient taking Upadacitinib (Janus kinase inhibitor) and Prednisone (corticosteroid) that do not increase the risk of bleeding?
What is the appropriate management for a patient with hypercholesterolemia and hyperlipidemia?
What type of ultrasound, arterial or venous, is used for diagnosing Deep Vein Thrombosis (DVT)?
What is the recommended treatment duration of valtrex (valacyclovir) for an immunocompetent adult with a herpes simplex virus type 1 (HSV-1) lesion on the upper lip and nose?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.